Carfilzomib, which is a proteasome inhibitor under development as a treatment for multiple myeloma, has recently been shown to be a safe and effective treatment for myeloma patients with kidney failure, chromosomal abnormalities, or peripheral neuropathy. These results will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Additionally, ASH presenters will examine the effects of carfilzomib in patients who have previously been treated with Velcade (bortezomib) and in patients who are receiving carfilzomib in combination with…